Business Wire

DN-CAPITAL

9.7.2021 06:02:06 CEST | Business Wire | Press release

Share
DN Capital, Early Backer of Auto1, Shazam and OLX, Launches New $350m Fund to Shape Post-pandemic World

DN Capital, one of Europe’s most established Venture Capital firms, today announces the launch of its latest $350m (£220m, €300m) fund. In a year which has already seen four of the DN Capital portfolio reach billion dollar-plus valuations, the firm’s Fund V will back the most ambitious early stage entrepreneurs across Europe, the UK and the US, who are creating businesses built on the pandemic-accelerated surge in digital adoption, and developing technologies critical to the global recovery.

Under the leadership of private equity and VC stalwarts Nenad Marovac and Steve Schlenker - who head up a senior team with a combined 100 years-plus of investment experience - DN’s predominantly young and ambitious team has a consistent track record of partnering with some of Europe’s most promising startups, long before they became market leaders.

‘Think Big and Global”

Known for their ‘Think Big and Global’ approach to startup investing, the firm was one of Shazam’s earliest backers in 2004, and helped guide the London-born app through to Apple’s acquisition in 2018. DN Capital led the Series A round in Auto1, which floated on the German Stock Exchange earlier this year at a valuation over $10 billion and over 150x their entry price per share. Just recently in July 2021 the online eyewear retailer MrSpex also saw a strong IPO debut, valuing the company at over $1.0bn. DN Capital’s first billion dollar exit was Endeca which was sold to Oracle for $1.1bn in 2011. In its current portfolio US remittance business Remitly, digital staffing company Jobandtalent and the online education company GoStudent are amongst the latest unicorns and have recently closed billion-dollar financing rounds.

Fund V, which was substantially oversubscribed, will double-down on DN Capital’s strategy of finding and supporting the next generation of global category leaders specifically in its core fields of software, fintech, marketplaces and the consumer internet. Roughly two thirds of the firm’s investments have been made in Europe, through its London and Berlin hubs, with the remainder originating in its Silicon Valley office in Menlo Park.

For the journey

With a proven ability to identify founders with unicorn potential at the earliest stages, a worldwide advisor network, a deep 20-year track record, and a reputation for insightful business model understanding, DN Capital has established itself as a persistent outlier in European and US venture capital. It has proven to give founders the best possible platform for their scale-up journey, while being able to introduce its portfolio teams to top tier growth-stage investors.

“We’ve always preferred to let our founders and their incredible numbers talk for us,” says Nenad Marovac DN Capital’s founder. “When we say we only partner with the best, we mean it. We spend vast amounts of time with entrepreneurs understanding the market, their team, their product and to get to the heart of what they’re trying to achieve, long before we even talk about money. Then we work together with the entrepreneurs as partners to help them where they need it.

“The launch of our fifth fund gives us further scope to uncover new entrepreneurs with the biggest, brightest global ambitions. We pride ourselves on the fact that we work as hard as founders do to help them build their businesses, and this is something that’s going to be even more crucial as we, as a society, look to come back stronger following the pandemic,” he says.

‘Post-COVID fund’

DN Capital co-founder and managing partner Steve Schlenker believes the full impact of the pandemic on society, work, and behaviours is only just being understood, and that—when it happens--the recovery around the world will be powered by innovation and technology. “There are tech founders across the globe right now on critical missions to accelerate this recovery and help address the needs, and solve the biggest problems, of the post-COVID world,” he says. “At DN Capital we are committed to supporting them to achieve these goals.”

Partner Thomas Rubens adds: “We have backed numerous category defining businesses and we know what it takes to scale global companies. We have the youth and ambition in our team, as well as the huge global network, to be right at the cutting-edge of the next important trends. Especially those trends born out of the drastic, era-defining change we are witnessing today.”

“From the very start of our journey, Nenad, who was on our Board throughout, and the wider DN Capital team, supported us not just with strategic advice but helped us launch in the US, hire senior executives—including myself—and also introduced Apple,” says Andrew Fisher, Shazam’s former CEO and executive chairman. “The founder-investor relationship can be make-or-break for early stage entrepreneurs.”

Hakan Koc, co-founder and CEO at Auto1, said: ““ Since DN led the Series A in Auto1 we always enjoyed working with Nenad, Steve and the team. From the outset they saw the potential in us and Auto1 Group and understood how best to support us.”

Felix Ohswald, co-founder and CEO of GoStudent, said: “Expanding into 18 markets in just over two years is never easy but with DN Capital on our side we knew we could do it and in forging the connection with our next investors - DST, Softbank and Tencent - they helped us to take that next big leap.”

--ENDS--

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 15:37:00 CEST | Press release

The new SpeechLive Legal AI Assistant reduces the administrative burden on legal professionals through customizable document drafting powered by speech recognition tuned for legal terminology Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent an

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye